; and (2) any research findings that do not weigh the value of each year of life gained from treatment equally for all patients no matter their severity of illness, age, or pre-existing disability. (f) Definitions In this section: (1) The term independent value assessment means an economic analysis that— (A) analyzes the benefits of a particular drug for the average patient and for various subgroups of patients, as determined by the Secretary, and the benefits of the drug on a standalone basis and in comparison with other approved treatments, including— (i) an economic analysis of direct benefits to the patient, including to the quality and duration of life of the patient; and (ii) an economic analysis of indirect benefits, including— (I) benefits to family members, employers, and caregivers of the patient; and (II) benefits to the health care system, including savings to public- and private-sector payers resulting from potential use of health services that is avoided due to the benefits of the particular drug; and (B) includes, for the current year and each of the next 4 years, an estimate of a price, price range, or a proposed value-based payment arrangement for the particular drug that is commensurate with the economic benefits of the particular drug, including a list and explanation of the factors that support the estimated price, price range, or proposed value-based payment arrangement. (C) includes— (i) an estimate of a price, price range, or a proposed value-based payment arrangement for the particular drug that— (I) is tied to the Consumer Price Index for medical services starting with the year the drug was approved or licensed; and (II) is commensurate with the economic benefits of the particular drug